Tegilerdine: Inject Tegilerdine in the induction of general anesthesia
Sufentanil: Inject Sufentanil in the induction of general anesthesia
Study summary
In patients undergoing general anesthesia with planned tracheal intubation , a prospective, randomized, controlled study was conducted to record the occurrence of cough 2 minutes after injection of Sufentanil or Tegilerdine. The cough was graded based on the frequency and duration: Grade I, no cough; Grade II, a single mild cough; Grade III, multiple coughs with duration \<1 second; Grade IV, continuous coughing with a duration \>15 seconds.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria:
1. Age between 18 and 65 years, 18 ≤ BMI (kg/m²) ≤ 30;
2. ASA grade I \~ III;
3. Scheduled elective surgery under general anesthesia with tracheal intubation.
Exclusion Criteria:
1. Patients with chronic cough (cough lasting \>8 weeks) or asthma;
2. Patients with a history of allergy to the drugs used during the study;
3. Patients with severe cardiovascular disease, intracranial lesions, eye lesions, or lung lesions.
Primary outcome measure(s)
Incidence of choking cough response — 2 minutes after administration Two minutes after administration of the study drugs (Tegilerdine/Sufentanil), any clear coughing action is considered an 'occurrence'.
Trial sites (1)
Facility
City
Region
Status
The Affiliated Lianyungang Hospital of Xuzhou Medical University
Lianyungang
Jiangsu
Recruiting
More The First People's Hospital of Lianyungang trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.